Literature DB >> 8484972

Validity of the histopathological criteria used for diagnosing dysplastic naevi. An interobserver study by the pathology subgroup of the EORTC Malignant Melanoma Cooperative Group.

P E de Wit1, B van't Hof-Grootenboer, D J Ruiter, R Bondi, E B Bröcker, J P Cesarini, N Hastrup, K Hou-Jensen, R M MacKie, E Scheffer.   

Abstract

Ten (dermato)pathologists studied 50 cutaneous melanocytic lesions including common naevocellular naevi, dysplastic naevi (DN), melanomas in situ and invasive primary melanomas, with emphasis on the histological criteria of DN. Using a standardised form, 20 defined histopathological features were scored (semi)quantitatively. Concordance of diagnosis, efficacy and reproducibility of features were investigated. DN were distinguished well from the other entities (mean Po 0.87). Agreement on the degree of atypia of DN was low. The reproducibility of the scoring was best for the following features: irregular nests, lymphohistiocytic infiltrate, marked junctional proliferation and large nuclei. The overall values of these features to discriminate between DN and non-DN were better than for the other features studied. Using the presence of at least three of the four features as a condition for the diagnosis of DN, values for sensitivity, specificity and positive and negative predictive values were 0.86, 0.91, 0.96 and 0.73, respectively. On the basis of the results these features seem best suited as histological criteria for the diagnosis of DN.

Entities:  

Mesh:

Year:  1993        PMID: 8484972     DOI: 10.1016/s0959-8049(05)80419-8

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  11 in total

1.  Histological features used in the diagnosis of melanoma are frequently found in benign melanocytic naevi.

Authors:  C Urso; F Rongioletti; D Innocenzi; D Batolo; S Chimenti; P L Fanti; R Filotico; R Gianotti; M Lentini; C Tomasini; M Pippione
Journal:  J Clin Pathol       Date:  2005-04       Impact factor: 3.411

Review 2.  The dysplastic naevus.

Authors:  W J Mooi
Journal:  J Clin Pathol       Date:  1997-09       Impact factor: 3.411

3.  Interobserver reproducibility of histological features in cutaneous malignant melanoma.

Authors:  C Urso; F Rongioletti; D Innocenzi; C Saieva; D Batolo; S Chimenti; R Filotico; R Gianotti; M Lentini; C Tomasini; A Rebora; M Pippione
Journal:  J Clin Pathol       Date:  2005-11       Impact factor: 3.411

4.  The dysplastic nevus: from historical perspective to management in the modern era: part I. Historical, histologic, and clinical aspects.

Authors:  Keith Duffy; Douglas Grossman
Journal:  J Am Acad Dermatol       Date:  2012-07       Impact factor: 11.527

Review 5.  Dysplastic nevi and melanoma.

Authors:  Alisa M Goldstein; Margaret A Tucker
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-04       Impact factor: 4.254

6.  A nationwide survey of observer variation in the diagnosis of thin cutaneous malignant melanoma including the MIN terminology. CRC Melanoma Pathology Panel.

Authors: 
Journal:  J Clin Pathol       Date:  1997-03       Impact factor: 3.411

Review 7.  From melanocytes to melanomas.

Authors:  A Hunter Shain; Boris C Bastian
Journal:  Nat Rev Cancer       Date:  2016-04-29       Impact factor: 60.716

8.  Diagnostic assessment of two novel proliferation-specific antigens in benign and malignant melanocytic lesions.

Authors:  P Rudolph; T Lappe; C Schubert; D Schmidt; R M Parwaresch; E Christophers
Journal:  Am J Pathol       Date:  1995-12       Impact factor: 4.307

9.  NRAS and BRAF mutations in melanoma-associated nevi and uninvolved nevi.

Authors:  Philipp Tschandl; Anna Sophie Berghoff; Matthias Preusser; Sebastian Burgstaller-Muehlbacher; Hubert Pehamberger; Ichiro Okamoto; Harald Kittler
Journal:  PLoS One       Date:  2013-07-08       Impact factor: 3.240

Review 10.  Pre-Cancerous Lesions in the Oral and Maxillofacial Region: A Literature Review with Special Focus on Etiopathogenesis.

Authors:  Soussan Irani
Journal:  Iran J Pathol       Date:  2016
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.